<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038349</url>
  </required_header>
  <id_info>
    <org_study_id>CYP-D-001</org_study_id>
    <nct_id>NCT01038349</nct_id>
  </id_info>
  <brief_title>Applications for Methotrexate Optimization in Rheumatoid Arthritis</brief_title>
  <acronym>AMORA</acronym>
  <official_title>Applications for Methotrexate Optimization in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cypress Bioscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cypress Bioscience, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to enable the study sponsor to assess the impact of a marketed or&#xD;
      validated blood test has on physicians' clinical treatment decision making when treating RA&#xD;
      patients who have been taking methotrexate.&#xD;
&#xD;
      Ultimately, the blood test will allow treating physicians to modify current methotrexate&#xD;
      therapy in partially responding Rheumatoid Arthritis (RA) patients' therapy, on an&#xD;
      individualized basis, as a means of improving clinical outcomes.&#xD;
&#xD;
      The study requires a blood sample from RA patients who have been on methotrexate therapy for&#xD;
      a minimum of 3 months and are having an inadequate response to therapy. Physicians will then&#xD;
      be provided with the results of the test indicating the methotrexate polyglutamate (active&#xD;
      metabolites of methotrexate) levels in the patient's red blood cells as a means to help&#xD;
      determine whether a patient's exposure to methotrexate has been optimized.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is currently enrolling individuals who have an established diagnosis of RA and are&#xD;
      receiving methotrexate as part of their therapy. Patients are required to submit a blood&#xD;
      sample. There is no cost to volunteers who participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the impact of the Avise PG test on physician's clinical treatment decision making process when assessing RA patients having an inadequate response to current MTX therapy.</measure>
    <time_frame>Outcome is determined following the receipt of Avise PG test result</time_frame>
  </primary_outcome>
  <enrollment type="Actual">256</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Avise PG - Diagnostic test</intervention_name>
    <description>Eligible patients will receive an Avise PG test</description>
    <other_name>Measure of methotrexate polyglutamates test</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care and Rheumatology Clinics&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to read, understand, and sign the informed consent form&#xD;
&#xD;
          -  Able to read, write, and speak English&#xD;
&#xD;
          -  â‰¥18 years of age&#xD;
&#xD;
          -  Diagnosed with RA within past 24 months (waiver)&#xD;
&#xD;
          -  Taking oral methotrexate therapy for a minimum of 3 months&#xD;
&#xD;
          -  Considered to have an insufficient response to methotrexate and therefore a candidate&#xD;
             for change to therapy, including changing MTX dose or changing route of delivery, or&#xD;
             adding or switching DMARDs (including but not limited to biologic DMARDs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure of the study center, study physician or study patient to the Avise PG&#xD;
             laboratory test&#xD;
&#xD;
          -  Patients with known abnormal hepatic and or hematological parameters&#xD;
&#xD;
          -  Use of prednisone &gt;10mg/day (or its equivalent)&#xD;
&#xD;
          -  Rheumatologic diagnosis other than primary RA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Michael Gendreau, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cypress Bioscience, Inc.</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>June 1, 2011</last_update_submitted>
  <last_update_submitted_qc>June 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>R. Michael Gendreau, M.D., Ph.D, Vice President, Chief Medical Officer</name_title>
    <organization>Cypress Bioscience, Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

